InDex Gets Cash Boost For Phase III Ulcerative Colitis Drug

Swedish Firm's Cobitolimod Could Be A Blockbuster

 
• By Kevin Grogan

The Stockholm-based company is in a position to start the Phase III program for its ulcerative colitis candidate after raising over $64m in a rights issue.

Swedish flags
Index flying the flag for Swedish biotechs • Source: Archive

More from Financing

More from Business